TD Cowen raised the firm’s price target on Incyte (INCY) to $128 from $101 and keeps a Buy rating on the shares. The company presented a roadmap to potentially triple revenue excluding Jakafi by 2029, the analyst tells investors in a research note. The firm says that with multiple Phase 3 readouts and initiations, 2026 “is a year of both execution and delivery” for Incyte.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Balancing Near‑Term Strength and Post‑Jakafi Uncertainty: Why Incyte Merits a Hold Rating
- Incyte: Diversifying Beyond Jakafi With a High-Value Late-Stage Pipeline and Disciplined Growth Strategy
- Incyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors
- Incyte price target raised to $90 from $80 at Goldman Sachs
- Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study